Unknown PHASE2 INTERVENTIONAL 3-arm NCT05006170

Pharmacokinetics, Safety, and Efficacy of Dolutegravir Dispersible Tablets in Young Children Living With HIV

Sponsor: Chulalongkorn University

Updated 5 times since 2021 Last updated: Nov 15, 2021 Started: Aug 3, 2021 Primary completion: Feb 28, 2022 Completion: Jun 30, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Pediatric HIV Infection, this trial is ongoing. The trial is conducted by Chulalongkorn University and has accumulated 5 data snapshots since 2021. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Aug 2023 — Jul 2024 [monthly]

Unknown Status PHASE2

Status: Recruiting → Unknown Status
Dec 2021 — Aug 2023 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting · Phase: None → PHASE2
Sep 2021 — Dec 2021 [monthly]

Not Yet Recruiting

First recorded

Aug 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Chulalongkorn University

Data source: Chulalongkorn University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bangkok, Thailand